Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury

Biochem Biophys Res Commun. 2002 Nov 22;299(1):14-7. doi: 10.1016/s0006-291x(02)02573-1.

Abstract

Transcription factor NF-kappaB is associated with inflammatory response and cell survival. Under inactive condition, NF-kappaB is sequestered in the cytoplasm by an anchor protein, inhibitor of NF-kappaB (IkappaB). NF-kappaB was shown to be activated during ischemic brain injury. In the present study we have investigated the role of NF-kappaB in ischemic brain injury using a recombinant adenovirus expressing a dominant negative form of IkappaB (Adv/IkappaBdn) to specifically inhibit NF-kappaB activation. Our data demonstrated that cortical injection of Adv/IkappaBdn significantly reduced ischemic brain injury following permanent occlusion of the middle cerebral artery (MCAO) in rats, showing 55% reduction (p<0.01, n=8) in total ischemic lesion or 80% reduction (p<0.001) in the cortical area with Adv/IkappaBdn expression. Similarly, Adv/IkappaBdn expression significantly decreased neurological deficits (37% reduction over controls, p<0.01, n=8). These data provide further evidence for the role of NF-kappaB/IkappaB in ischemic brain injury and suggest that inhibition of NF-kappaB is neuroprotective in focal stroke.

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Brain / pathology*
  • Brain Ischemia / pathology*
  • Genes, Dominant
  • I-kappa B Proteins / genetics*
  • I-kappa B Proteins / pharmacology
  • Immunohistochemistry
  • Male
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Regional Blood Flow

Substances

  • I-kappa B Proteins
  • NF-kappa B
  • Nfkbia protein, rat
  • NF-KappaB Inhibitor alpha